Skip to content

Dose Optimization and Prediction Modeling of Hydromorphone in Adductor Canal Block for Total Knee Replacement Analgesia

Study on Dose Optimization and Prediction Model of Hydroxycobalamin for Tibialis Anterior Nerve Block in Total Knee Arthroplasty

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113467
Enrollment
Unknown
Registered
2025-11-28
Start date
2024-11-06
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee pain

Interventions

intervention gruop1:The adductor canal block was performed using a mixture of 2 µg/kg hydromorphone (2 mL) and 0.25% ropivacaine (18 mL)
control gruop:0.25% ropivacaine 20ml for adductor canal block
intervention gruop2:The adductor canal block was performed using a mixture of 4 µg/kg hydromorphone (2 mL) and 0.25% ropivacaine (18 mL)
intervention gruop3:The adductor canal block was performed using a mixture of 6 µg/kg hydromorphone (2 mL) and 0.25% ropivacaine (18 mL)
intervention gruop4:The adductor canal block was performed using a mixture of 8 µg/kg hydromorphone (2 mL) and 0.25% ropivacaine (18 mL)
intervention gruop5:The adductor canal block was performed using a mixture of 10 µg/kg hydromorphone (2 mL) and 0.25% ropivacaine (18 mL)

Sponsors

The Second affiliated Hospital of Zhejiang Chinese Medicine University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Osteoarthritis (2018 edition); 2. Age 50 ~ 80 years old; 3. American Society of Anesthesiologists (ASA) grade I to III; 4. body mass index (BMI) 18-25 kg/m^2; 5. No moderate or severe cardiopulmonary insufficiency; 6. No severe hypertension, diabetes, no history of major surgery or mental illness; 7. Patient signs informed consent.

Exclusion criteria

Exclusion criteria: 1. Chronic opioid users (continuous use for =4 weeks, e.g., morphine, fentanyl, etc.); 2. History of ropivacaine allergy; 3. Chronic alcohol abuse or alcohol dependence; 4. Patients with hepatic or renal insufficiency; 5. Individuals with poor cardiopulmonary function; 6. Previous vascular surgery on the affected lower limb; 7. Non-ambulatory patients (wheelchair-bound long-term); 8. Infection at the puncture site; 9. Uncooperative or non-communicative patients; 10. Patients with immune system disorders.

Design outcomes

Primary

MeasureTime frame
VAS score after total knee replacement;Quadriceps muscle strength score after total knee replacement;Number of PCIA compressions after total knee replacement;Ramasy sedation score after total knee replacement;BCS comfort score after total knee replacement;Use of supplemental remedial analgesics;Postoperative 24-hour serum IL-6 levels;Postoperative 24-hour serum IL-10 levels;Postoperative 24-hour serum PGE2 levels;

Secondary

MeasureTime frame
Incidence of postoperative adverse reactions;

Countries

China

Contacts

Public ContactLi Yuebing

The Second affiliated Hospital of Zhejiang Chinese Medicine University

lyb1853@zcmu.edu.cn+86 159 8812 1853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026